TY - JOUR T1 - COVID-19 Vulnerability of Transgender Women With and Without HIV Infection in the Eastern and Southern U.S. JF - medRxiv DO - 10.1101/2020.07.21.20159327 SP - 2020.07.21.20159327 AU - Tonia C. Poteat AU - Sari L. Reisner AU - Marissa Miller AU - Andrea L. Wirtz AU - on behalf of the American Cohort To Study HIV Acquisition Among Transgender Women (LITE) Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/24/2020.07.21.20159327.abstract N2 - Background COVID-19 is a new global pandemic and people with HIV may be particularly vulnerable. Gender identity is not reported, therefore data are absent on the impact of COVID-19 on transgender people, including transgender people with HIV. Baseline data from the American Cohort to Study HIV Acquisition Among Transgender Women in High Risk Areas (LITE) Study provide an opportunity to examine pre-COVID vulnerability among transgender women.Setting Atlanta, Baltimore, Boston, Miami, New York City, Washington, DCMethods Baseline data from LITE were analysed for demographic, psychosocial, and material factors that may affect risk for COVID-related harms.Results The 1020 participants had high rates of poverty, unemployment, food insecurity, homelessness, and sex work. Transgender women with HIV (n=273) were older, more likely to be Black, had lower educational attainment, and were more likely to experience material hardship. Mental and behavioural health symptoms were common and did not differ by HIV status. Barriers to healthcare included being mistreated mistreatment, uncomfortable providers, and past negative experiences; as well as material hardships, such as cost and transportation. However, most reported access to material and social support – demonstrating resilience.Conclusions Transgender women with HIV may be particularly vulnerable to pandemic harms. Mitigating this harm would have positive effects for everyone, given the highly infectious nature of this coronavirus. Collecting gender identity in COVID-19 data is crucial to inform an effective public health response. Transgender-led organizations’ response to this crisis serve as an important model for effective community-led interventions.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; TP and AW have received research grants from Viiv Healthcare and Gilead Sciences, MM has received grant support from Gilead Sciences; no other relationships or activities that could appear to have influenced the submitted work.Clinical Protocols https://www.researchprotocols.org/2019/10/e14704/ Funding StatementResearch reported in this publication was jointly supported by the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute of Child Health and Human Development of the National Institutes of Health under Award Number UG3/UH3AI133669 (MPI: ALW and SLR). Research reported in this publication was also supported by HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA), Washington DC Department of Health. The LITE study is also appreciative of support from the CFAR at partner institutions, including JHU (P30AI094189), Emory University (P30AI050409), Harvard University (P30AI060354), DC CFAR (AI117970), and the University of Miami (P30AI073961). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or HAHSTA. TP received support for her effort from the National Institute of Minority Health and Health Disparities (R01MD013499).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Johns Hopkins School of Medicine Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the LITE Study upon request. Requests for data must be accompanied by a concept note submitted via https://www.litestudy.org and must be consistent with the LITE Study collaboration policies listed on the website. https://www.litestudy.org ER -